🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
51.09
-2.32 (-4.34%)
Nov 20, 2026, 12:43 PM EST - Market open

MBX Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
59.3719.210.986.983.86
Research & Development
100.9778.8657.2228.3321.3
Operating Expenses
160.3398.0668.1935.3125.16
Operating Income
-160.33-98.06-68.19-35.31-25.16
Interest Expense
-----0.37
Interest & Investment Income
13.487.473.341.70.35
Other Non Operating Income (Expenses)
-----0.07
EBT Excluding Unusual Items
-146.86-90.58-64.85-33.61-25.26
Gain (Loss) on Sale of Investments
1.763.612.931.040.03
Other Unusual Items
-----0.9
Pretax Income
-145.1-86.97-61.92-32.56-26.14
Net Income
-145.1-86.97-61.92-32.56-26.14
Net Income to Common
-145.1-86.97-61.92-32.56-26.14
Net Income Growth
-----
Shares Outstanding (Basic)
47371111
Shares Outstanding (Diluted)
47371111
Shares Change
39.51%243.01%944.70%52.73%-
EPS (Basic)
-3.09-2.38-5.82-31.96-39.18
EPS (Diluted)
-3.09-2.38-5.82-31.96-39.18
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-99.33-81.88-55.56-32.11-23.56
Free Cash Flow Per Share
-2.12-2.24-5.22-31.52-35.33
EBITDA
-159.99-97.81-67.95-35.15-25.11
D&A For EBITDA
0.340.250.240.160.06
EBIT
-160.33-98.06-68.19-35.31-25.16
SEC Filings: 10-K · 10-Q